Alain Cuna1, Joanne M Lagatta2, Rashmin C Savani3, Shilpa Vyas-Read4, William A Engle5, Rebecca S Rose5, Robert DiGeronimo6, J Wells Logan7, Michel Mikhael8, Girija Natarajan9, William E Truog1, Matthew Kielt7, Karna Murthy10,11, Isabella Zaniletti12, Tamorah R Lewis1. 1. Children's Mercy Kansas City, University of Missouri, Kansas, Missouri, USA. 2. Department of Pediatrics, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 3. University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA. 5. Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA. 6. Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. 7. Division of Neonatology, Nationwide Children's Hospital, Columbus, Ohio, USA. 8. Neonatal-Perinatal Medicine Division, Children's Hospital of Orange County, Orange, California, USA. 9. Department of Pediatrics, Wayne State University, Detroit, Missouri, USA. 10. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. 11. Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 12. Children's Hospital Association, Lenexa, Kansas, USA.
Abstract
OBJECTIVE: To evaluate the association between the time of first systemic corticosteroid initiation and bronchopulmonary dysplasia (BPD) in preterm infants. STUDY DESIGN: A multi-center retrospective cohort study from January 2010 to December 2016 using the Children's Hospitals Neonatal Database and Pediatric Health Information System database was conducted. The study population included preterm infants <32 weeks' gestation treated with systemic corticosteroids after 7 days of age and before 34 weeks' postmenstrual age. Stepwise multivariable logistic regression was used to assess the association between timing of corticosteroid initiation and the development of Grade 2 or 3 BPD as defined by the 2019 Neonatal Research Network criteria. RESULTS: We identified 598 corticosteroid-treated infants (median gestational age 25 weeks, median birth weight 760 g). Of these, 47% (280 of 598) were first treated at 8-21 days, 25% (148 of 598) were first treated at 22-35 days, 14% (86 of 598) were first treated at 36-49 days, and 14% (84 of 598) were first treated at >50 days. Infants first treated at 36-49 days (aOR 2.0, 95% CI 1.1-3.7) and >50 days (aOR 1.9, 95% CI 1.04-3.3) had higher independent odds of developing Grade 2 or 3 BPD when compared to infants treated at 8-21 days after adjusting for birth characteristics, admission characteristics, center, and co-morbidities. CONCLUSIONS: Among preterm infants treated with systemic corticosteroids in routine clinical practice, later initiation of treatment was associated with a higher likelihood to develop Grade 2 or 3 BPD when compared to earlier treatment.
OBJECTIVE: To evaluate the association between the time of first systemic corticosteroid initiation and bronchopulmonary dysplasia (BPD) in preterm infants. STUDY DESIGN: A multi-center retrospective cohort study from January 2010 to December 2016 using the Children's Hospitals Neonatal Database and Pediatric Health Information System database was conducted. The study population included preterm infants <32 weeks' gestation treated with systemic corticosteroids after 7 days of age and before 34 weeks' postmenstrual age. Stepwise multivariable logistic regression was used to assess the association between timing of corticosteroid initiation and the development of Grade 2 or 3 BPD as defined by the 2019 Neonatal Research Network criteria. RESULTS: We identified 598 corticosteroid-treated infants (median gestational age 25 weeks, median birth weight 760 g). Of these, 47% (280 of 598) were first treated at 8-21 days, 25% (148 of 598) were first treated at 22-35 days, 14% (86 of 598) were first treated at 36-49 days, and 14% (84 of 598) were first treated at >50 days. Infants first treated at 36-49 days (aOR 2.0, 95% CI 1.1-3.7) and >50 days (aOR 1.9, 95% CI 1.04-3.3) had higher independent odds of developing Grade 2 or 3 BPD when compared to infants treated at 8-21 days after adjusting for birth characteristics, admission characteristics, center, and co-morbidities. CONCLUSIONS: Among preterm infants treated with systemic corticosteroids in routine clinical practice, later initiation of treatment was associated with a higher likelihood to develop Grade 2 or 3 BPD when compared to earlier treatment.
Authors: Halana V Whitehead; Christopher C McPherson; Zachary A Vesoulis; Barbara A Cohlan; Rakesh Rao; Barbara B Warner; F Sessions Cole Journal: J Pediatr Date: 2020-08 Impact factor: 4.406
Authors: Yong Y Han; Joseph A Carcillo; Shekhar T Venkataraman; Robert S B Clark; R Scott Watson; Trung C Nguyen; Hülya Bayir; Richard A Orr Journal: Pediatrics Date: 2005-12 Impact factor: 7.124
Authors: K Murthy; R C Savani; J M Lagatta; I Zaniletti; R Wadhawan; W Truog; T R Grover; H Zhang; J M Asselin; D J Durand; B L Short; E K Pallotto; M A Padula; F D Dykes; K M Reber; J R Evans Journal: J Perinatol Date: 2014-03-20 Impact factor: 2.521
Authors: Ravi M Patel; Sarah Kandefer; Michele C Walsh; Edward F Bell; Waldemar A Carlo; Abbot R Laptook; Pablo J Sánchez; Seetha Shankaran; Krisa P Van Meurs; M Bethany Ball; Ellen C Hale; Nancy S Newman; Abhik Das; Rosemary D Higgins; Barbara J Stoll Journal: N Engl J Med Date: 2015-01-22 Impact factor: 91.245
Authors: Michele C Walsh; Qing Yao; Jeffrey D Horbar; Joseph H Carpenter; Shoo K Lee; Arne Ohlsson Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Peter G Davis; Barbara Schmidt; Robin S Roberts; Lex W Doyle; Elizabeth Asztalos; Ross Haslam; Sunil Sinha; Win Tin Journal: J Pediatr Date: 2009-11-18 Impact factor: 4.406